Form 4: Alumis CMO Jorn Drappa Exercises Stock Options

Alumis Inc. Chief Medical Officer Jorn Drappa exercised stock options to acquire 26,852 shares of common stock.

Summary

• Chief Medical Officer Jorn Drappa exercised options to acquire 11,317 shares at $8.84 per share.
• Jorn Drappa exercised options to acquire 15,535 shares at $5.06 per share.
• Following these transactions, the reporting person holds 59,339 shares of common stock directly.
• The transactions were executed on May 22, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard administrative exercise of vested equity compensation by an executive.

Positives

• Internal leadership demonstrates continued commitment to equity ownership in the company.

Negatives

• None identified.

Risks

• Vesting of remaining options is subject to the reporting person's continuous service to the issuer.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the reporting of insider equity transactions.

Industry Context

StockSavvy.ai notes that routine option exercises by C-suite executives in the biotechnology sector are standard components of executive compensation packages and generally do not signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The exercise of employee stock options is a standard practice for executive retention in the biopharmaceutical industry.
• The transaction volume is consistent with typical executive equity management for a company of Alumis's market capitalization.

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensatory equity exercises.

Next Steps

• Continued vesting of remaining derivative securities according to the established schedule.

Key Dates

Keywords

Alumis, ALMS, Form 4, Insider Trading, Stock Options, Biotech